Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS (PCA)

Delayed Quote. Delayed  - 01/17 11:21:32 am
15.02 EUR   -1.18%
2016 PCAS : Acquisition of a leading R&D Center
2016 PCAS : Acquisition of a leading r&d center
2016 PCAS : at China INTER LUBRIC 2016
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

PCAS : quarterly financial reporting Sep 30, 2011

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/07/2011 | 05:40pm CET

Quarterly financial reporting
As of 30 September 2011

 

 

Business update

 

(in thousands of euros)20112010% change
 First Quarter44,05341,4346,3%
 including Pharmaceutical Synthesis27,14726,6032,0%
 including Specialty Chemicals16,90614,83114,0%
 Second Quarter41,78942,698-2,1%
 including Pharmaceutical Synthesis26,45728,100-5,8%
 including Specialty Chemicals15,33214,5985,0%
 Third Quarter33,48133,658-0,5%
 including Pharmaceutical Synthesis19,53018,3946,2%
 including Specialty Chemicals13,95115,264-8,6%
 Total as of 30 September119,323117,7901,3%
 including Pharmaceutical Synthesis73,13473,0970,1%
 including Specialty Chemicals46,18944,6933,3%

 

 

 

The PCAS Group's consolidated revenues at 30 September 2011came in 1.3% higher than the same period the previous year.

 

Pharmaceutical Synthesis
Over the first five months of the year, business was affected by the planned reduction in the contribution by the new contract between PCAS and Sanofi, effective since 31 May 2010. Excluding this contract, the Exclusive and Non-Exclusive Pharma business is up 10.5% at 30 September 2011.
Fine Specialty Chemicals
With growth of 3.3% at 30 September 2011, the Fine Specialty Chemicals business contracted by 8.6% during the third quarter of 2011 in relation to 2010, reflecting the economic slowdown seen since the summer.

 

Key operations and events for the quarter

 

No important events likely to have a significant impact on the company's business or situation occurred during the third quarter of 2011.

 

Outlook for the current year

 

The high level of sales expected for the fourth quarter should lead to earnings growth in 2011.

 

 

Next date :  2011 earnings, February 22nd, 2012

 

 

About PCAS
PCAS is a fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability.

 

Longjumeau, October 7th, 2011

 

PCAS_T3_2011_EN:
http://hugin.info/143512/R/1553112/478624.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PCAS via Thomson Reuters ONE

HUG#1553112
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PCAS
2016 PCAS : Acquisition of a leading R&D Center
2016 PCAS : Acquisition of a leading r&d center
2016 PCAS : at China INTER LUBRIC 2016
2016 PCAS : net sales as of 30 September, 2016
2016 PCAS : ex-dividend day for interim dividend
2016 PCAS : 1st half 2016 earnings report continued organic growth
2016PCAS : half-yearly earnings release
2016 PCAS : Net sales for the 1st half of 2016
2016 PCAS : SUSTAINED GROWTH IN NET SALES FOR THE 1st HALF OF 2016
2016 PCAS : signs a global distribution agreement with MilliporeSigma
More news
Sector news : Pharmaceuticals - NEC
08:40aDJASTRAZENECA : Sets New Deadlines for MYSTIC Trial
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/13DJLONDON MARKETS : FTSE 100 Continues Record Run, Rising For 14th Day In A Row
01/13 FTSE hits record highs, extends historic winning streak
01/12DJCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic -- Update
More sector news : Pharmaceuticals - NEC
Advertisement
Financials (€)
Sales 2016 194 M
EBIT 2016 16,5 M
Net income 2016 9,70 M
Debt 2016 33,6 M
Yield 2016 1,23%
P/E ratio 2016 21,41
P/E ratio 2017 17,61
EV / Sales 2016 1,36x
EV / Sales 2017 1,27x
Capitalization 230 M
More Financials
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Full-screen chart
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 13,3 €
Spread / Average Target -13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Vincent Touraille CEO & Financial Communications Contact
Christian Moretti Chairman
Pierre Schreiner Deputy Chief Executive Officer-Operations
Eric Moissenot Deputy CEO-Finance & Administration
Gérard Guillamot Director-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PCAS7.99%245
JOHNSON & JOHNSON-0.53%311 773
ROCHE HOLDING LTD.2.75%203 077
PFIZER INC.0.12%197 343
NOVARTIS AG-1.48%187 856
MERCK & CO., INC.5.89%171 880
More Results